Step-by-Step Ascent, Unleashing New Forces | Call for Nominations: 2026 Future Healthcare 100 Awards Launched!
Viewing the global trends in healthcare innovation alongside China’s developmental momentum, China is emerging as a core growth pole through a unique “tri-polar drive” model: high-frequency and active trading of healthcare innovation assets injects efficient kinetic energy into the circulation of Chinese innovative technologies; a significant tilt in global capital allocation has established a solid financial foundation for industrial innovation in China; and the intensive commercialization of “China-first” innovations continues to deliver incremental industrial value. The synergistic resonance among these three forces is propelling China’s healthcare innovation from a phase of technological following to one of ecosystem leadership, becoming a key variable reshaping the competitive landscape of the global healthcare industry.
Building on the industry insights and industrial connectivity value accumulated over nine editions of the selection,VCBeat’s 2026 Top 100 Future Healthcare Companies Selection Officially Launches.We will focus on the pioneering entities that drive the efficient circulation of innovative assets, facilitate the commercialization of “China-first” achievements, and anchor global investment value trends. At this new starting point for industrial innovation, we will continuously uncover breakthrough practices in new technologies, new transactions, and new ecosystems—Using awards as a bridge, we document the trajectory of China’s medical innovation leap and uncover the core forces defining the next wave of industry growth!
The 2026 Future Healthcare Top 100 selection anchors on the core direction of “Innovation, Transaction, and Empowerment in China’s Healthcare Industry,” achieving a comprehensive upgrade of the evaluation system. This year’s selection features two core segments:2026 Future Healthcare Top 100 List, 2026 Future Healthcare Top 100 Awards.
(Click to view full-size image)
PART.01 Ranking of Non-Listed Companies
This ranking is targeted at non-listed companies in the healthcare and medical sector. The selection process is based on the VB100 Value Assessment Model, proceeding through stages of self-nomination by enterprises, review by the VB100 Review Committee, cross-review by supporting institutions, and final approval by the Expert Committee, fromInnovative Medical Devices and Intelligent Manufacturing, Innovative Pharmaceuticals and Biological Products, Innovative Health Services and Industry Chain ServicesSelect the top 100 non-listed companies by valuation ranking in each of the three major sectors.
I. Top 100 List of Innovative Medical Devices and Intelligent Manufacturing
Eligible Candidates:
It primarily covers R&D and manufacturing enterprises in the fields of medical devices, medical consumables, and in vitro diagnostics (IVD)-related medical device products, as well as enterprises that independently innovate in medical devices and intelligent manufacturing product development supported by digital technologies (such as cloud computing, big data, and artificial intelligence). This includes, but is not limited to, enterprises in the following areas: high-value consumables (cardiovascular/orthopedic/ophthalmic/dental/neurological/blood purification/non-vascular intervention, etc.); low-value consumables (medical hygiene materials and dressings/anesthesia consumables/disinfection consumables/injection and puncture consumables, etc.); medical equipment (imaging/patient monitoring/radiotherapy/physical and chemical analysis/dialysis/laser/surgical/rehabilitation, etc.); home-use medical devices (blood pressure monitors/blood glucose meters/ventilators/oxygen concentrators/massagers, etc.); AI-enabled medical devices (smart wearable devices/AI medical imaging, etc.); medical robots (surgical robots/rehabilitation robots, etc.); and in vitro diagnostics (biochemical diagnostics/immunodiagnostics/molecular diagnostics/POCT/microbiological diagnostics/hematology diagnostics, etc.).
Eligibility Requirements:
A. Non-listed companies in the fields of innovative medical devices and intelligent manufacturing;
II. Top 100 Innovative Pharmaceuticals and Biological Products List
Eligible Candidates:
Primarily covers pharmaceutical companies engaged in R&D, production, innovative drugs and biologics, or providing innovative therapies, as well as enterprises independently conducting R&D of innovative pharmaceuticals and biologics supported by digital technologies (such as cloud computing, big data, and artificial intelligence). This includes, but is not limited to, companies in fields related to biological drugs and biologics for prevention, treatment, diagnosis, and healthcare (e.g., antibodies, vaccines, blood products, cell therapy, gene therapy), chemical drugs (e.g., generics, innovative drugs), and traditional Chinese medicine (e.g., traditional Chinese medicines, innovative Chinese medicines).
Eligibility Criteria:
III. Top 100 List of Medical and Health Innovation Services
Selection Criteria:
Primarily covers enterprises that directly provide health services to patients, as well as those offering industrial chain services to industry stakeholders. This includes, but is not limited to, the following categories:**Terminal Health Services:*** **Non-public Medical Services:** Private hospitals (general, specialized, independent, or chain hospitals and clinics) and physician groups.* **Internet and Telehealth Services:** Internet hospitals, mobile health platforms, telemedicine services, and patient consultation service platforms.* **Health Management and Rehabilitation Services:** Health consulting, online education, rehabilitation nursing, and professional physical examination services.* **Precision Diagnosis and Health Intervention Services:** In vitro diagnostics (IVD) and precision diagnostic services, third-party testing and imaging services, and health services for chronic diseases, neurological disorders, and cognitive behavioral conditions.* **Retail Health Terminals:** Pharmacies and other health retail outlets.**Industrial Chain Services:*** **R&D and Production Support Services:** Pharmaceutical and medical device CRO/CMO/CDMO/CSO, life science tools and services, and upstream raw materials, consumables, and equipment.* **Industrial Operation and Upgrade Services:** Smart hospital construction services, medical IoT support services, and upgrade services for R&D, marketing, and distribution sectors.* **Industrial Support and Financial Services:** Innovative payment solutions, medical insurance and financial services, cold chain logistics, third-party sterilization services, and innovative channel and marketing services.
Eligibility Criteria:
A. Non-listed enterprises innovating in health services and industrial chain services;
I. Top 50 Listed Healthcare Companies by Innovation Strength
This ranking targets listed companies in the healthcare and medical sector. The list revolves aroundCorporate Market Capitalization and Annual Growth Rate, Revenue from Innovative Businesses and Annual Growth Rate, R&D Expenditure and Annual Growth Rate6The VB100 Index for Innovation Strength of Listed Companies is constructed based on key indicators, aiming to provide data-driven insights into corporate capital value and strategic innovation, market value and commercial innovation, as well as technological value and product innovation. By thoroughly analyzing companies’ innovation value and growth trends, the index seeks to identify benchmark enterprises that demonstrate high innovation capability and robust growth performance under innovation-driven development.
The selection criteria for this ranking are listed companies in China's healthcare and medical sector, with industry classifications based on the Shenwan Industry Classification Standards, specifically coveringChemical Pharmaceuticals, Traditional Chinese Medicine (TCM), Biological Products, Pharmaceutical Commerce, Medical Devices, and Healthcare ServicesSix Major Subsectors; Enterprises Must Complete by December 31, 2025Shanghai Stock Exchange,Shenzhen Stock Exchange, Hong Kong Stock ExchangeorNasdaq Stock Market, New York Stock Exchangelisting on other overseas stock exchanges.
Selection Criteria:
A. Capital Value and Strategic Innovation Capability: An index constructed based on corporate market capitalization as of December 31, 2025, and the year-on-year market cap growth rate in 2025;
E. Data Processing: The index evaluation model will apply Min-Max normalization to each indicator to eliminate differences in data magnitude and enable fair comparison across multiple dimensions.
II. Top 50 Ranking of Listed Healthcare Companies by Global Expansion Strength
This ranking targets listed companies in the healthcare and medical sector. The list centers onOverseas Revenue Amount, Proportion of Overseas Revenue to Total Revenue, Overseas RevenueYear-on-Year (YoY)AmplificationThree Core Metrics Construct the VB100 Index for Listed Companies’ Global Expansion Strength, Aiming to Analyze Enterprises’ Overseas Revenue Scale, Contribution, and Growth Through Data, Deeply Dissect the Value and Expansion Trends of Healthcare Companies’ Global Layouts, and Identify Benchmark Enterprises with Strong Overseas Revenue Capabilities and Sustained Growth Performance.
This ranking evaluates listed companies in China’s healthcare and medical sector, with industry classifications based on the Shenwan Industry Classification Standards, specifically coveringChemical Pharmaceuticals, Traditional Chinese Medicine (TCM), Biological Products, Pharmaceutical Commerce, Medical Devices, and Medical ServicesSix Major Sub-sectors; Enterprises Must Complete by December 31, 2025Shanghai Stock Exchange,SZSE, Hong Kong Stock ExchangeorNASDAQ, NYSElisting on other overseas stock exchanges.
★ Top 50 Innovators in China’s Healthcare Industry
● Award Introduction
Innovation in the healthcare industry has entered a phase driven by multi-stakeholder collaboration. Breakthroughs in frontier technologies by scientists, the translation of innovative achievements by entrepreneurs, and resource linking and empowerment by investors—each party’s innovative practices exert significant influence within the industry. Together, they form an interconnected chain of industrial innovation, where the individual value of any single role is no longer sufficient to fully sustain the core driving force of industrial innovation.
Although previous awards covered diverse groups, the segmented recognition based on single roles failed to fully reflect the collaborative value of each role in industrial innovation. The 2026 Future Healthcare Top 100 Figures Award has been integrated and upgraded into“Top 50 Influential Innovators in China’s Healthcare Industry”, aligning with the development logic of collaborative industrial innovation.
“Top 50 Innovators in China’s Healthcare Industry”Covering a diverse array of innovative figures with entrepreneurs, investors, and scientists as the core candidates, the selection criteria encompass not only individual innovative practices in technology, business, and capital, along with their industry influence, but also highlight the ecological impact of cross-role collaboration on industrial innovation and upgrading. The award aims to break down role barriers, precisely identify and honor key figures who exert significant influence across the entire chain of industrial innovation, thereby establishing benchmark role models for collaborative innovation in the healthcare industry.
● Nomination Requirements
(1) Entrepreneurs
A. Founders and core executives (e.g., CEO, COO, CTO) of healthcare companies;
B. Lead at least one core product/service innovation during the review year, such as holding core patents, launching products that are first-of-their-kind in China or globally, pioneering new business models in niche sectors, or building industry collaboration platforms;
C. Promote the large-scale implementation of innovative achievements within the review year, such as obtaining market approval for products, significantly expanding the coverage of services across regions or populations, and achieving sustained growth in corporate revenue and/or market share;
D. Possesses industry influence. Their business practices or management philosophies serve as a model and driver within their specific niche sector, garnering industry-wide recognition;
E. The enterprise operates in compliance with regulations, and the individual maintains a good reputation. The enterprise has no record of major legal or regulatory violations in business operations within the past three years, and its business activities comply with relevant regulatory requirements in the healthcare sector. The individual possesses a positive public image, is free from negative industry publicity, and is capable of leading the enterprise to proactively assume corporate social responsibility.
(II) Investors
A. Investors, including partners at investment institutions and heads of strategic investment at multinational corporations (MNCs) or listed companies;
B. During the review year, led or played a core role in investing in at least five innovative projects in the healthcare sector, focusing on cutting-edge segments, with the invested projects demonstrating technological innovation;
C. During the review year, facilitated invested innovative projects in breaking through key growth milestones by means of capital injection and linking industrial chain resources, such as promoting subsequent financing rounds, connecting industrial cooperation resources, assisting products in entering clinical/commercialization stages, and supporting product overseas expansion, etc.;
D. Possesses industry influence. Its investment logic or strategic layout serves as a benchmark and reference for the healthcare investment sector, and its portfolio companies have garnered significant industry attention and recognition;
E. The institution is compliant, and the individual has a good reputation. The affiliated investment institution has no record of major violations of laws or regulations in professional practice within the past three years, and its business operations comply with relevant regulatory requirements of the capital market; the individual enjoys a positive industry reputation and is free from negative public sentiment.
(3) Scientists
A. Core scientific researchers in the field of healthcare at universities and research institutes;
B. Led the research and development of at least one original technology or core product during the review year, possessing relevant core patents or cutting-edge achievements; for example, pioneering new technological pathways or breaking through industry “chokehold” technical barriers.
C. Promote the industrial translation of the aforementioned technologies/achievements within the review year, such as by reaching cooperative R&D agreements with enterprises, implementing technology licensing, advancing achievements to the clinical stage, or achieving small-scale industrial production.
D. Possesses industry influence. Its R&D achievements play a leading role in its specific technical field, and the related research or translational practices have garnered widespread attention and reference within the industry;
E. The institution is compliant, and the individual has a good reputation. The employing institution has no record of major research misconduct in the past three years, and its research activities comply with academic ethics and industry regulatory requirements; the individual maintains a strong academic reputation with no adverse records such as academic misconduct.
PART.02 Institutional Award
★China's Healthcare Industry: Top 50 Value Investment and Service Institutions
● Award Introduction
The value growth of innovative healthcare assets hinges on deep integration with professional institutions. Investment firms inject capital and connect industrial resources, while transaction service providers offer specialized support for financing, mergers and acquisitions, and initial public offerings. The bidirectional value co-creation between these two types of institutions and enterprises forms the core synergy that addresses the pain points of “insufficient funding, limited resources, and lack of professional services,” thereby driving innovative assets from R&D blueprints to global markets.
Previous selections of investment and transaction service institutions largely focused on the institutions’ own capabilities, failing to fully reflect their co-created value with innovative assets. The 2026 Future Healthcare Top 100 Institution Awards have been integrated and upgraded into“Top 50 Value Investment and Service Institutions in China’s Healthcare Industry”, thereby providing a more comprehensive assessment of the institution’s actual contribution to the growth of innovation assets.
“Top 50 Value Investment and Service Institutions in China’s Healthcare Industry”Focusing on the full-lifecycle growth needs of innovative healthcare assets, this initiative primarily covers value-investment institutions and transaction-service providers. It not only explores the value-added service capabilities of investment firms and enterprises in dimensions such as capital injection, resource linkage, and strategic synergy, but also recognizes the professional collaboration achievements of transaction-service agencies and enterprises in financing, mergers and acquisitions, and other stages. Ultimately, it provides a high-quality reference for institutional cooperation based on “capital empowerment + professional service support” to facilitate the value realization of innovative healthcare assets.
● Eligibility Criteria
(I) Value Investment Institutions
A. Legally registered and continuously operating investment institutions both domestically and internationally (including VC, PE, CVC, etc.), which must have established RMB funds, USD funds, or dual-currency funds dedicated to investing in China’s healthcare industry;
B. Over the past three years, the institution has focused its strategic investments on innovative healthcare assets, covering areas including but not limited to medical devices, biopharmaceuticals, digital health, and healthcare services;
C. Provide in-depth, value-added post-investment services to invested healthcare companies, including but not limited to collaboratively formulating differentiated strategic plans, connecting with clinical and supply chain resources on the industrial side, assisting in building professional core teams, and leveraging ecosystem resources to facilitate follow-on financing, thereby practically empowering companies to achieve growth breakthroughs in key areas such as R&D and commercialization;
D. The institution must have completed at least 10 investment cases related to innovative healthcare assets within the past three years, and be able to provide evidence of post-investment co-creation outcomes for these cases;
E. The institution operates in compliance with regulations and has not been subject to any major administrative penalties or regulatory warnings related to fund fundraising or investment operations within the past three years.
(2) Transaction Empowerment Institutions
A. Legally registered and continuously operating transaction-enabling institutions both domestically and internationally, including financial advisory firms (FA), securities companies with sponsorship and underwriting qualifications, law firms and accounting firms with securities service qualifications, etc.;
B. Over the past three years, the institution has focused on transaction services in the field of innovative healthcare assets, covering scenarios including but not limited to financing matchmaking for innovative assets, mergers and acquisitions, restructuring, initial public offerings (IPOs), and refinancing;
C. Engage in deep value-enabling transaction services with healthcare innovation enterprises and value-oriented investment institutions, effectively facilitating the efficient execution of transactions and the rational realization of asset value;
D. The institution must have completed at least 10 transaction service cases related to innovative healthcare assets within the past three years, and be able to provide proof of co-created outcomes for these cases (such as transaction completion certificates, client service evaluations, or data demonstrating financing/valuation growth facilitated by the asset realization);
E. The institution operates in compliance with regulations, has not been subject to any major administrative penalties or regulatory warnings related to transaction services within the past three years, and maintains valid and legally effective professional qualifications.
PART.03PlatformAward
★ Top 50 Ecological Innovation and Empowerment Institutions in China's Healthcare Industry
● Award Introduction
The healthcare industry is entering a critical phase of ecosystem-driven collaborative innovation. Platform-based carriers—such as industrial parks, incubators, and innovation centers—have become core nodes in the ecological infrastructure, linking upstream and downstream segments of the industry chain, aggregating global innovation elements, and nurturing high-potential, high-quality enterprises. Their capabilities in ecosystem building, resource integration, and value empowerment serve as strategic pillars for driving the clustered advancement of industrial sectors and accelerating the commercialization of innovative achievements.
As the industrial ecosystem undergoes iterative upgrades, the differentiated enabling value of diverse platforms such as incubators and innovation centers has become increasingly prominent. The previous Park Awards have struggled to fully capture the core supporting forces of the industrial ecosystem. The 2026 Future Healthcare Top 100 Platform Awards will expand the scope of the former Park Awards and be officially upgraded to“Top 50 Innovation and Empowerment Platforms in China’s Healthcare Industry”, thereby adapting to the new development paradigm of symbiotic coexistence and mutual promotion among diverse carriers within the industrial ecosystem.
“Top 50 Platforms for Ecosystem Innovation and Empowerment in China’s Healthcare Industry”Focusing on diverse platform types such as industrial parks, incubators, and innovation centers, this selection evaluates both the value and effectiveness of each platform in terms of spatial infrastructure, resource synergy, project incubation, and technological empowerment, as well as their regional industrial radiation capabilities. It also delves into the differentiated core values of various platforms. By broadening perspectives and exploring deeper values, this initiative aims to identify benchmark enabling platforms, establishing referenceable models for ecological infrastructure that support the high-quality, ecosystem-driven development of the healthcare industry.
● Eligibility Criteria
(I) Industrial Parks
A. Healthcare industrial parks legally established and operated within China, with business focus on frontier sectors such as innovative pharmaceuticals, innovative medical devices, digital health, and healthcare services;
B. Centered on building an innovation ecosystem, it plays a pivotal role in driving the transformation and breakthrough of the healthcare industry by upgrading industrial technology systems, cultivating scientific and technological innovation capabilities, and fostering collaborative innovation across the industrial chain;
C. Establish a full-chain innovation service ecosystem encompassing technology R&D, achievement commercialization, financing support, market promotion, and talent development, successfully attracting and nurturing a cohort of healthcare enterprises with industry influence, thereby creating an industrial ecosystem effect characterized by “aggregation of innovation entities + resource linkage and empowerment”;
D. Continuously explore innovative service models with a global perspective, empower the international innovation strategies of park-based enterprises by introducing advanced international innovative resources and connecting to global technology networks, and promote the open and collaborative development of the industrial ecosystem.
(2) Incubator
A. A professional healthcare incubator legally established and operated within China, focusing on nurturing startups in innovative pharmaceuticals, innovative medical devices, digital health, and other related fields;
B. Centered on empowering innovation projects, we provide critical ecosystem support for the growth of healthcare startups by facilitating technology implementation, validating business models, and connecting innovative resources;
C. Build an innovation incubation ecosystem covering entrepreneurial coaching, R&D support, capital matchmaking, and industrial resource integration, successfully incubating a batch of high-growth-potential medical and healthcare startups, and creating an innovative agglomeration effect characterized by “project incubation + ecosystem empowerment”;
D. Continuously innovate incubation service models, integrate domestic and international innovation networks, introduce cutting-edge global technologies, capital, and industrial resources, empower technological iteration and market expansion of incubated projects, and promote cross-domain synergy within the innovation ecosystem.
(3) Innovation Center
A. Innovation centers in the healthcare sector that are legally established and operational within China (including joint entities co-founded by enterprises and universities), focusing on the research, development, and translation of core technologies in areas such as innovative drugs, high-end medical devices, and digital-intelligent healthcare;
B. Centered on building a technological innovation ecosystem, lead the direction of technological innovation in the medical and health industry by tackling key technologies, establishing collaborative industry-academia-research systems, and exporting industrial technical standards;
C. Build a technological innovation service ecosystem covering R&D support, pilot-scale testing facilities, technology transfer matchmaking, and industrial chain empowerment; successfully implement a batch of breakthrough industry technologies and empower enterprises across the industrial chain to achieve technological upgrades;
D. Continuously deepen international technological collaboration, build an open innovation ecosystem by partnering with top-tier research institutions and introducing cutting-edge technological achievements, and promote the global deployment of core technologies and industrial empowerment.
★Top 50 Most Investable Companies in China’s Healthcare Industry
● Award Introduction
Listed companies play a core role in leading the scaling-up of the industry, while non-listed enterprises serve as emerging drivers of industrial innovation. Clearly identifying the investment value of these two types of enterprises not only enables precise matching of high-quality targets in the capital market but also facilitates the concentration of industrial resources toward entities with growth potential, thereby providing key support for the coordinated development of innovation and mature business models in the medical and healthcare industry.
The Enterprise Awards of this edition are anchored in the core theme of “Innovation Advancement and Investment Value Across the Full Corporate Lifecycle,” integrating previous sub-categories such as Annual Leader Enterprises, Annual Outstanding Enterprises, and Annual Innovative Enterprises, and upgrading them into “Top 50 Most Investable Companies in China’s Healthcare Industry”, simultaneously covering both listed and unlisted entities, to centrally showcase high-quality investment assets across different stages of industry development.
“Top 50 Most Investable Companies in China’s Healthcare Industry” Centered on “innovation-driven advancement” and guided by “investment value,” the selection process provides the capital market with comprehensive, high-quality options across the full investment cycle, covering both “mature targets” and “high-potential targets.” It also establishes “benchmarks for the practical implementation of innovation at different development stages” within the healthcare industry. Furthermore, it helps listed companies link with industrial resources and strengthen their industry influence, while assisting non-listed companies in connecting with capital and accelerating the commercialization of innovative achievements.
● Eligibility Criteria
(1) Listed Companies
A. Healthcare companies listed on mainstream capital markets in China and overseas, with business focused on core niche sectors such as innovative drugs, innovative medical devices, digital health, and innovative healthcare services;
B. Strong financial growth performance. Revenue from core business operations has shown steady growth, with profitability of core businesses ranking at a relatively high level within the industry. The company maintains R&D investment intensity aligned with business development to support technological and product innovation and iteration;
C. Possesses long-term industry competitiveness. Holds a favorable market position within its niche segment, maintains a competitive pipeline of products under development or a core product portfolio, and consistently delivers innovative achievements with significant technical barriers;
D. Investor recognition and reasonable valuation range. The valuation falls within a reasonable range for the specific niche sector, garnering sustained attention and recognition from mainstream investment institutions; market sentiment is positive, and investor confidence remains stable;
E. Corporate Compliance Operations. No major legal violations in the past three years, such as information disclosure irregularities or penalties from pharmaceutical regulatory authorities; standardized financial information disclosure and operational practices that comply with industry regulatory requirements.
(II) Non-listed Companies
A. Privately held healthcare enterprises legally registered within China, with business operations focused on core niche sectors such as innovative pharmaceuticals, innovative medical devices, digital health, and innovative medical services;
B. Significant Core Innovation Achievements. The entity possesses exclusive core technologies or products, and the related achievements have entered a critical stage of industrialization promotion;
C. Strong commercialization prospects. The niche sector in which the company operates offers ample growth potential and industry vitality. The company has a clear and actionable commercialization pathway, and its core products/services have demonstrated definite market acceptance and potential for commercial value.
D. Sustainable Financing Capability. The core team possesses extensive experience in the healthcare industry and strong resource integration capabilities; it has received multiple rounds of endorsement from professional investment institutions, with sufficient capital reserves to support continuous business development and the realization of key outcomes;
E. Corporate Compliance in Operations. No major records of pharmaceutical regulatory penalties, data security violations, or other significant infractions in the past three years; business operations comply with regulatory and ethical requirements in the healthcare sector.
★ Top 50 Most Innovative Products and Technologies in China's Healthcare Industry
● Award Introduction
China’s healthcare industry has transitioned from a phase of technological catch-up to one of exporting original resources. In the early years, domestically developed innovative products were rare exceptions; today, there is a surge in products launched and pioneered for the first time in China, which are no longer niche labels within the industry. These first-in-China and first-of-their-kind products not only precisely address unmet clinical needs but have also become core forces in global medical competition, substantially enhancing China’s international voice in healthcare innovation.
The Product Awards selection has been integrated and upgraded to“Top 50 Most Innovative Products and Technologies in China’s Healthcare Industry”, with a core focus on the breakthrough value of China’s original innovations, concentrating on uncovering and showcasing the leading strength of Chinese medical innovation in the global arena.
“Top 50 Most Innovative Products and Technologies in China’s Healthcare Industry”, anchored in the dual value of “China-originated + Global Breakthrough,” covering China’s first-launch and first-of-their-kind products and solutions across three major fields: biotechnology, digital technology, and intelligent medical device technology. On one hand, it showcases the top-tier achievements of Chinese medical innovation in these areas, establishing an industry benchmark for “China-first Innovations”; on the other hand, it helps these breakthrough products connect with clinical resources, industrial partnerships, and global channels, accelerating the implementation process from “China-first Launch” to “Global Application,” thereby further enhancing the international influence of Chinese medical innovation.
● Eligibility Criteria
(1) Biotechnology-Oriented Products/Solutions
A. Biotechnology products, including but not limited to innovative products in the fields of cell therapy, gene therapy, gene editing, cancer immunotherapy, regenerative medicine, tissue engineering, regenerative medical materials, precision diagnostics and testing, organoids and organ-on-a-chip, nanomedicine, innovative vaccines, and blood products;
B. Innovative products selected for participation must demonstrate certain advantages over other similar products in terms of the technologies employed, specialty-specific clinical needs, specialty-specific therapeutic outcomes, and process efficiency; or they must achieve innovation in concepts, technologies, products, platforms, services, or other aspects within their respective research fields.
C. Innovative products nominated for selection must have no negative reports regarding patent disputes, academic misconduct, or falsification of clinical trial data;
D. Innovative products submitted for consideration should demonstrate promising market application prospects and commercialization potential, have completed or be currently undergoing relevant clinical trials, and be poised to achieve scaled production and sales within the foreseeable future.
(II) Products/Solutions in the Digital Technology Sector
A. Digital technology products, including but not limited to innovative products in technical fields such as large medical AI models (AI-based imaging diagnosis/AI-based pathology diagnosis/AI-assisted drug development/AI-powered medical Q&A), VR/AR-enabled healthcare (surgical assistance/rehabilitation management/patient education/medical training), and digital therapeutics;
B. Candidate innovative products must demonstrate certain advantages over similar products in terms of applied technologies, healthcare informatization, optimization of medical workflows, and enhancement of patient experience; or they must have achieved innovations in algorithms, software, hardware, platforms, services, or other aspects within their respective research fields.
C. Candidate innovative products must have no negative reports regarding technical infringement, data breaches, or violations of user privacy;
D. Innovative products submitted for consideration should demonstrate certain market application prospects and commercialization potential. They should have completed or be undergoing relevant technical validation and user testing, with the expectation of achieving large-scale deployment and application within a foreseeable future period.
(III) Products/Solutions in the Field of Intelligent Medical Device Technology
A. Intelligent medical device technology products, including but not limited to innovative products in fields such as intelligent devices (diagnostic equipment/imaging equipment/rehabilitation equipment/monitoring equipment), innovative implantable and interventional consumables, and brain-computer interfaces;
B. Candidate innovative products must demonstrate significant advantages over similar competing products in terms of underlying technology, design philosophy, and functional implementation; they must also exhibit clear clinical value in practical medical applications, including but not limited to improving diagnostic accuracy, shortening treatment cycles, alleviating patient suffering, and enhancing rehabilitation outcomes.
C. Innovative products selected for participation must have no negative reports regarding patent disputes, academic fraud, or fabrication of clinical trial data;
D. Innovative products submitted for selection should demonstrate certain market application prospects and commercialization potential, have completed or be currently undergoing relevant clinical trials, and are expected to achieve scaled production and sales within a foreseeable future.
Selection Process:
Submission Method:
Registration Consultation:
